Ulotaront hydrochloride by Sumitomo Pharma America for Generalized Anxiety Disorder (GAD): Likelihood of Approval

Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Generalized Anxiety Disorder (GAD).

Lula aims to establish Brazil as pharmaceutical bellwether to South America – Pharmaceutical Technology

Despite criticism of his support for Nicolas Maduro, President Lula maintained that the Brasilia Summit showed promising signs of South American reintegration. (Photo by EVARISTO

June 28, 2023

MesoCancerVac by Amphera for Metastatic Pancreatic Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

July 8, 2023

Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss

The TDR Three Key Takeaways: Positive Clinical Progress: Cybin Inc. has reported significant advancements in its clinical programs, notably achieving a primary efficacy endpoint in

February 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.